Skip to main content
Top
Published in: Rheumatology International 5/2017

01-05-2017 | Observational Research

Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India

Authors: Altaf Hussain, Amit Rawat, Ankur Kumar Jindal, Anju Gupta, Surjit Singh

Published in: Rheumatology International | Issue 5/2017

Login to get access

Abstract

The objective of this study is to determine autoantibody profile in children with juvenile dermatomyositis (JDM). Children who were diagnosed with JDM (either recently diagnosed during the study period or follow-up patients) were included in the study. Autoantibodies were detected with commercially available Immunodot kit. Thirty patients were included in the study. Nine out of thirty patients (30%) were positive for one of the 12 autoantibodies tested. Anti-SRP antibody was most common antibody detected in 3 patients followed by anti-MDA-5 antibody in 2 patients; while anti-Jo1 antibody, anti-TIF1-γ antibody, anti-Mi-2 antibody, and anti-PM-Scl antibody were positive in 1 patient each. A different disease phenotype was observed with each autoantibody. The patient with anti-Jo1 antibody had a severe systemic disease in the form of interstitial lung disease; patients with anti-MDA-5 antibody and anti-Mi2 antibody had more severe skin disease with mild muscle disease and patients with anti-SRP antibody had significant skin and muscle disease. Anti-TIF1-γ and anti-PM-Scl antibodies were seen in patients with features of overlap syndrome (myositis–scleroderma). Estimation of autoantibodies may serve as an adjunct tool in delineating and defining distinct clinical phenotypes in children diagnosed with juvenile dermatomyositis. They may also help in prognostication.
Literature
1.
go back to reference Symmons DP, Sills JA, Davis SM (1995) The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 34(8):732–736CrossRefPubMed Symmons DP, Sills JA, Davis SM (1995) The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 34(8):732–736CrossRefPubMed
2.
go back to reference Reeder MJ, Wetter DA, Li X, Davis MDP (2010) Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 146(1):26–30PubMedCentral Reeder MJ, Wetter DA, Li X, Davis MDP (2010) Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 146(1):26–30PubMedCentral
3.
go back to reference McCann LJ, Juggins AD, Maillard SM et al (2006) The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 year. Rheumatol Oxf Engl 45(10):1255–1260CrossRef McCann LJ, Juggins AD, Maillard SM et al (2006) The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 year. Rheumatol Oxf Engl 45(10):1255–1260CrossRef
4.
go back to reference Wedderburn LR, Rider LG (2009) Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol 23(5):665–678CrossRefPubMedPubMedCentral Wedderburn LR, Rider LG (2009) Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol 23(5):665–678CrossRefPubMedPubMedCentral
5.
go back to reference Montecucco C, Ravelli A, Caporali R et al (1990) Autoantibodies in juvenile dermatomyositis. Clin Exp Rheumatol 8(2):193–196PubMed Montecucco C, Ravelli A, Caporali R et al (1990) Autoantibodies in juvenile dermatomyositis. Clin Exp Rheumatol 8(2):193–196PubMed
6.
go back to reference Wedderburn LR, McHugh NJ, Chinoy H et al (1990) HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis–scleroderma overlap. Rheumatology 46(12):1786–1791CrossRef Wedderburn LR, McHugh NJ, Chinoy H et al (1990) HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis–scleroderma overlap. Rheumatology 46(12):1786–1791CrossRef
7.
go back to reference Ghirardello A, Bassi N, Palma L et al (2013) Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 15(6):335CrossRefPubMed Ghirardello A, Bassi N, Palma L et al (2013) Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 15(6):335CrossRefPubMed
8.
go back to reference Tansley SL, McHugh NJ, Wedderburn LR (2013) Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res Ther 15(2):211CrossRefPubMedPubMedCentral Tansley SL, McHugh NJ, Wedderburn LR (2013) Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res Ther 15(2):211CrossRefPubMedPubMedCentral
9.
go back to reference Hervier B, Wallaert B, Hachulla E et al (2010) Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatol Oxf Engl 49(5):972–976CrossRef Hervier B, Wallaert B, Hachulla E et al (2010) Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatol Oxf Engl 49(5):972–976CrossRef
10.
go back to reference Kalluri M, Sahn SA, Oddis CV et al (2009) Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 135(6):1550–1556CrossRefPubMed Kalluri M, Sahn SA, Oddis CV et al (2009) Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 135(6):1550–1556CrossRefPubMed
11.
go back to reference Singh S, Bansal A (2006) Twelve years experience of juvenile dermatomyositis in North India. Rheumatol Int 26(6):510–515CrossRefPubMed Singh S, Bansal A (2006) Twelve years experience of juvenile dermatomyositis in North India. Rheumatol Int 26(6):510–515CrossRefPubMed
12.
go back to reference Robinson AB, Hoeltzel MF, Wahezi DM et al (2014) Clinical characteristics of children with juvenile dermatomyositis: the childhood arthritis and rheumatology research alliance registry. Arthritis Care Res 66(3):404–410CrossRef Robinson AB, Hoeltzel MF, Wahezi DM et al (2014) Clinical characteristics of children with juvenile dermatomyositis: the childhood arthritis and rheumatology research alliance registry. Arthritis Care Res 66(3):404–410CrossRef
13.
go back to reference Gunawardena H, Betteridge ZE, McHugh NJ. (2009) Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatol Oxf Engl 48(6):607–612CrossRef Gunawardena H, Betteridge ZE, McHugh NJ. (2009) Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatol Oxf Engl 48(6):607–612CrossRef
14.
go back to reference Rider LG, Miller FW, Targoff IN et al (1994) A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum 37(10):1534–1538CrossRefPubMed Rider LG, Miller FW, Targoff IN et al (1994) A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum 37(10):1534–1538CrossRefPubMed
15.
go back to reference Rider LG, Katz JD, Jones OY (2013) Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 39(4):877–904CrossRefPubMed Rider LG, Katz JD, Jones OY (2013) Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 39(4):877–904CrossRefPubMed
16.
go back to reference Sato S, Hoshino K, Satoh T et al (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 60(7):2193–2200CrossRefPubMed Sato S, Hoshino K, Satoh T et al (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 60(7):2193–2200CrossRefPubMed
17.
go back to reference Hall JC, Casciola-Rosen L, Samedy L-A et al (2013) Anti-mda5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res 65(8):1307–1315CrossRef Hall JC, Casciola-Rosen L, Samedy L-A et al (2013) Anti-mda5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res 65(8):1307–1315CrossRef
18.
go back to reference Nakashima R, Imura Y, Kobayashi S et al (2010) The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatol Oxf Engl 49(3):433–440CrossRef Nakashima R, Imura Y, Kobayashi S et al (2010) The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatol Oxf Engl 49(3):433–440CrossRef
19.
go back to reference Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65(1):25–34CrossRefPubMedPubMedCentral Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65(1):25–34CrossRefPubMedPubMedCentral
20.
go back to reference Gono T, Sato S, Kawaguchi Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatol Oxf Engl 51(9):1563–1570.CrossRef Gono T, Sato S, Kawaguchi Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatol Oxf Engl 51(9):1563–1570.CrossRef
21.
go back to reference Koga T, Fujikawa K, Horai Y et al (2012) The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatol Oxf Engl 51(7):1278–1284.CrossRef Koga T, Fujikawa K, Horai Y et al (2012) The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatol Oxf Engl 51(7):1278–1284.CrossRef
22.
go back to reference Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T (2011) Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 158(4):675–677CrossRefPubMed Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T (2011) Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 158(4):675–677CrossRefPubMed
23.
24.
go back to reference Shah M, Mamyrova G, Targoff IN et al (2013) The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92(1):25–41CrossRef Shah M, Mamyrova G, Targoff IN et al (2013) The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92(1):25–41CrossRef
25.
go back to reference Rider LG, Shah M, Mamyrova G et al (2013) The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92(4):223–243CrossRef Rider LG, Shah M, Mamyrova G et al (2013) The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92(4):223–243CrossRef
26.
go back to reference Gunawardena H, Wedderburn LR, North J et al (2008) Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatol Oxf Engl 47(3):324–328CrossRef Gunawardena H, Wedderburn LR, North J et al (2008) Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatol Oxf Engl 47(3):324–328CrossRef
27.
go back to reference Targoff IN, Mamyrova G, Trieu EP et al (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54(11):3682–3689CrossRefPubMed Targoff IN, Mamyrova G, Trieu EP et al (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54(11):3682–3689CrossRefPubMed
28.
go back to reference Targoff IN, Johnson AE, Miller FW (1990) Antibody to signal recognition particle in polymyositis. Arthritis Rheum 33(9):1361–1370CrossRefPubMed Targoff IN, Johnson AE, Miller FW (1990) Antibody to signal recognition particle in polymyositis. Arthritis Rheum 33(9):1361–1370CrossRefPubMed
29.
go back to reference Miller T, Al-Lozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73(4):420–428CrossRefPubMedPubMedCentral Miller T, Al-Lozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73(4):420–428CrossRefPubMedPubMedCentral
30.
go back to reference Hengstman GJD, ter Laak HJ, Egberts WTMV et al (2006) Anti-signal recognition particle autoantibodies: a marker of a necrotising myopathy. Ann Rheum Dis 65(12):1635–1638CrossRefPubMedPubMedCentral Hengstman GJD, ter Laak HJ, Egberts WTMV et al (2006) Anti-signal recognition particle autoantibodies: a marker of a necrotising myopathy. Ann Rheum Dis 65(12):1635–1638CrossRefPubMedPubMedCentral
31.
go back to reference Brouwer R, Hengstman GJ, Vree Egberts W et al (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60(2):116–123CrossRefPubMedPubMedCentral Brouwer R, Hengstman GJ, Vree Egberts W et al (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60(2):116–123CrossRefPubMedPubMedCentral
32.
go back to reference Rouster-Stevens KA, Pachman LM (2008) Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol 35(5):927–929PubMed Rouster-Stevens KA, Pachman LM (2008) Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol 35(5):927–929PubMed
33.
go back to reference Troyanov Y, Targoff IN, Payette M-P et al (2014) Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine (Baltimore) 93(24):318–332CrossRef Troyanov Y, Targoff IN, Payette M-P et al (2014) Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine (Baltimore) 93(24):318–332CrossRef
Metadata
Title
Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India
Authors
Altaf Hussain
Amit Rawat
Ankur Kumar Jindal
Anju Gupta
Surjit Singh
Publication date
01-05-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 5/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3707-4

Other articles of this Issue 5/2017

Rheumatology International 5/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.